As part of the National Institutes of Health (NIH) Roadmap for Medical Research, the NIH has announced a new Institutional Clinical and Translational Science Award (CTSA). Of the 37 CTSA applications that the NIH received, only 7 were funded, and CHORI, in collaboration with the Regents of the University of California, San Francisco (UCSF) was rated number 2 among them.

“It’s a really phenomenal opportunity,” says Bert Lubin, MD, CHORI President and Director of Medical Research. “The award will enable us to conduct even more adult and pediatric clinical and translational research in the east bay.”

The goal of the NIH initiative is to help multiple institutions across various scientific disciplines create integrative partnerships that encourage bench to bedside translation.

As CHORI is founded upon interdisciplinary collaborations with the goal of succeeding in the best translational research in the field, their partnership with UCSF represents a perfect pairing to achieve CTSA goals.

“With the new award, any researcher at CHORI will have access to any programs at UCSF,” explains Dr. Lubin. “This includes educational and technical resources, as well as joint collaborative research programs.”

While the award will not likely take effect until November at the earliest, CHORI expects funding of upwards of 1 million dollars. The CTSA will take the place of CHORI’s current clinical research center and enable it to grow exponentially, thereby confirming CHORI’s position as a leader in clinical and translational research for the east bay area both now and in years to come.

Back